ID Design Press, Skopje, Republic of Macedonia
Open Access Macedonian Journal of Medical Sciences. 2019 Sep 30; 7(18):3081-3084.
https://doi.org/10.3889/oamjms.2019.258
eISSN: 1857-9655
Global Dermatology

Acanthosis Nigricans – A Two-Sided Coin: Consider Metabolic Syndrome and Malignancies!

Uwe Wollina[1*], Gesina Hansel[1], Torello Lotti[2], Georgi Tchernev[3], Aleksandra Vojvodic[4], Ivanka Temelkova[3]

[1]Department of Dermatology and Allergology, Teaching Hospital Dresden - Friedrichstadt, Dresden, Germany; [2]Professor & Chair of Dermatology, University of Rome "G. Marconi", Rome , Italy; [3]Onkoderma - Clinic for Dermatology, Venereology and Dermatologic Surgery, General Skobelev 26, 1606, Sofia, Bulgaria; [4]Department of Dermatology and Venereology, Military Medical Academy of Belgrade, Belgrade, Serbia;

Citation: Wollina U, Hansel G, Lotti T, Tchernev G, Vojvodic A, Temelkova I. Acanthosis Nigricans – A Two-Sided Coin: Consider Metabolic Syndrome and Malignancies! Open Access Maced J Med Sci. 2019 Sep 30; 7(18):3081-3084. https://doi.org/10.3889/oamjms.2019.258

Keywords: Acanthosis nigricans; Metabolic syndrome; Malignancies; Paraneoplasia

***Correspondence:** Uwe Wollina. Department of Dermatology and Allergology, Teaching Hospital Dresden - Friedrichstadt, Dresden, Germany. E-mail: uwollina@gmail.com

Received: 05-Apr-2019; **Revised:** 04-May-2019; **Accepted:** 05-May-2019; **Online first:** 13-May-2019

Funding: This research did not receive any financial support

Competing Interests: The authors have declared that no competing interests exist

Abstract

BACKGROUND: Acanthosis nigricans (AN) is acquired hyperpigmentation of the intertriginous body regions. Histologically, AN is characterised by a thickened stratum corneum and a variable amount of acanthosis. Although benign and rarely symptomatic, AN may be a red flag for underlying pathologies.

CASE PRESENTATION: We analysed our patients with AN and could differentiate three different patterns, that are illustrated by one case report each. The is the benign AN associated with metabolic syndrome including obesity. The second type is the paraneoplastic AN malignancy which is associated with a wider range of malignancies. This type may occur before, after or with the clinical appearance of the malignancy. The third type is relapsing AN after complete remission. We present a patient who had a malignant AN and was treated successfully for his cancer. Years later, however, AN relapsed. In that case in association with the appearance of skin tags. Cancer restaging excluded a tumour relapse. His BMI was 31.2 kg/m^2, and the diagnosis of benign AN was confirmed.

CONCLUSIONS: The diagnosis of AN remains incomplete without screening for metabolic syndrome and/ or cancer. The combination of AN and skin tags is more often associated with metabolic syndrome. AN may be considered as a red flag for malignancies and the metabolic syndrome.

Introduction

Acanthosis nigricans (AN) is acquired hyperpigmentation of the intertriginous body regions and sometimes the periareolar skin. Besides the colour change, the disease most often remains asymptomatically. AN can occur as focal or diffuse papillomatous, hyperkeratotic, thickened lesions, which are symmetrically distributed. It rarely affects mucosa such as oral cavities.

Histologically, AN is characterised by a thickened stratum corneum and a variable amount of acanthosis. Horn pseudocysts can occasionally be present. The darker colour of AN is likely due to hyperkeratosis. A subtly mixed cellular infiltrates may be seen [1].

AN can develop in children, adolescents and adults. In children, the commonly affected body region is the neck followed by the axillae [2].

The prevalence of AN differs between ethnic groups. In the US, among native Americans, the prevalence was up to 34.2% followed by African Americans, Hispanics and Caucasians [3].

The pathogenesis of AN is complex. Elevated insulin concentrations result in direct and indirect activation of insulin-like growth factor (IGF)-1

receptors on suprabasal keratinocytes and fibroblasts. Other tyrosine kinase receptors such as epidermal growth factor receptor (EGFR) and fibroblast growth factor receptor (FGFR) may also contribute to hyperproliferation of keratinocytes and fibroblasts [4]. However, in obesity, the insulin concentrations are lower than warranted for such effects [5]. Extensive AN has been associated to hypochondroplasia with FGFR3 mutations [6]. Another possible, but the very rare association is a mutation of the *ELOV1* gene that encoded ELOVL fatty acid elongase 1, which catalyses elongation of saturated and monounsaturated C22-C26-very long-chain fatty acids [7]. Malignancy-associated AN might be explained by elevated levels of growth factors such as transforming growth factor (TGF-α), which can stimulate EGFR [8]. What causes the intertriginous areas to be most responsive has yet not been discovered.

Differential diagnoses

AN may resemble other disorders such as terra firma forme dermatosis [9], confluent and reticulated papillomatosis [10], berloque dermatitis, Riehl's melanosis, poikiloderma of Civatte [11].

Case reports

Case 1: A 48-year-old adipose male presented with hyperpigmented lesions on the thighs and scrotum. His body mass index (BMI) was 36 kg/m^2. He suffered from arterial hypertension and hyperlipidemia. On examination, we observed diffuse brownish hyperpigmentation of thighs and scrotal skin with papillomatosis (Figure 1). No treatment was warranted. We recommended nutritional counselling. The diagnosis of benign AN was confirmed.



Figure 1: Figure 1: Benign AN in an obese man

Case 2: A 39-year-old male presented with a relapse of intertriginous AN. His medical history was remarkable for kidney cancer in 2012 that was found after the first episode of AN and completely removed by surgery. The diagnosis of AN malignancy was confirmed. Five years later he demonstrated with a relapse of AN brownish-blackish hyperpigmentation in association with skin tags after complete remission in 2013 (Figure 2). We performed a computerised tomography of the abdomen and laboratory investigation that gave no hint of cancer relapse. His BMI was 31.2 kg/m^2. The diagnosis of benign AN was confirmed, and surgical excision of the thigh lesions was performed. We also recommended nutritional counselling.



Figure 2: Relapse of AN after successful kidney cancer treatment on the neck (a), groins, scrotum and thighs (b), and axillae (c, d). In the axillae, skin tags are seen

Case 3: A 62-year female presented with brownish hyperpigmentation of the neck, the back and the anal fold was presented by the department of oncology (Figure 3). She suffered from cholangiocarcinoma with peritoneal metastases and was treated by chemotherapy with gemcitabine and cisplatin — An developed shortly after tumour diagnosis. Malignant AN was confirmed, and anti-pruritic topical therapy with 5% polidocanol ointment was recommended.

Acanthosis nigricans and the metabolic syndrome

The major features of the metabolic syndrome are insulin resistance, visceral adiposity, atherogenic dyslipidemia and endothelial dysfunction [12]. AN has a strong association with overweight in adults, adolescents and children. Obesity in adults is defined as 30 kg/m², whereas in children and adolescents, overweight is defined as ≥ the 95th percentile of the

sex-specific BMI-for-age growth chart [13]. In a Turkish study on obese adults, 47.3% suffered from AN [14].



Figure 3: Malignant AN in a woman with cholangiocarcinoma

Overweight and obese children with AN demonstrate significantly higher levels for uric acid, fasting glycemia, insulin, glutamic oxalacetic transaminase, and homeostasis model assessment index than those without AN [15]. This suggests that AN is a marker of increased risk for metabolic syndrome in children, but the same has been demonstrated for other age groups as well [16]. Here, AN often is coexistent with multiple skin tags in contrast to malignant AN. Patients with AN showed be investigated for other symptoms of the metabolic syndrome such as blood pressure (BP), fasting lipoprotein profile, fasting glucose, haemoglobin A1C, fasting insulin, alanine aminotransferase (ALT), hyperlipidemia or hyperuricemia [17]. Women with polycystic ovary syndrome (POCS) show an increased prevalence of metabolic syndrome, type 2 diabetes (DM2) and cardiovascular disease. AN can be a cutaneous marker for POCS [18].

Acanthosis nigricans and cancer

AN is a possible paraneoplasia. Paraneoplasia is a disorder related to malignancy. It can frequently the first sign of a subjacent malignant tumour. Although relatively rare, they need to be recognised to make an early diagnosis and improve the prognosis of the malignancy [19]. The malignant conditions that have been associated with AN are tumours of the gastrointestinal tract, gynecologic and urogenital tumours among others, although gastric cancer is the most common (Table 1). In most cases, AN occurs concomitantly (61.3%), however, in 17.6% of cases, the lesions occur before the tumour detection and in 21% of cases, after the tumour has become obvious [20]. In contrast to non-malignant AN, mucous membranes, in particular, the oral cavity, can be affected.

Table 1: Malignant tumours associated with AN

Tumour	Reference
Breast cancer	Levine et al., 2010 [21]
Cholangiocarcinoma	Scully et al., 2001 [22]
Clear-cell renal carcinoma	Ferraz de Campos et al. 2016 [23]
Endometrial adenocarcinoma	Deen et al., 2017 [24]
Fallopian tube carcinoma	West et al., 2018 [25]
Gallbladder adenocarcinoma	Ziadi et al., 2009 [26]
Gastric adenocarcinoma	Yu et al., 2017 [27]
Gastric diffuse B-cell lymphoma	Mignogna et al., 2009 [28]
Gastrointestinal stromal tumor	Park et al., 2013 29]
Hepatocellular carcinoma	Antonio et al., 2018 [30]
Ileocecal adenocarcinoma	Gunduz et al., 2013 [31]
Insulinoma	Patra et al., 2016 [32]
Lung cancer	Owen 2016 [33]
Meningioma	Dainichi et al., 2008 [34]
Mycosis fungoides, Sèzary syndrome	Cheng et al., 2015 [35]; Fahmy et al., 2016 [36]
Ovarian cancer	Singh & Rai 2013 [37]
Pancreatic adenocarcinoma	McGinnes & Greer 2006 [38]
Prostate cancer	Tammaro et al., 2016 [39]
Rectal adenocarcinoma	Marschner & Reinhardt 2011 [40]
Sarcoma	Brantsch & Moehrle 2010 [41]

In conclusion, although AN by itself is most often an asymptomatic disease without significant impairment, the diagnosis is of great importance to identify underlying pathologies. The most important is the metabolic syndrome in overweight and obese patients of any age. The second is the role of malignant AN as an obligate paraneoplasia.

References

1. Schwartz RA. Acanthosis nigricans. J Am Acad Dermatol. 1994; 31(1):1-19. https://doi.org/10.1016/S0190-9622(94)70128-8

2. Sinha S, Schwartz RA. Juvenile acanthosis nigricans. J Am Acad Dermatol. 2007; 57(3):502-8. https://doi.org/10.1016/j.jaad.2006.08.016 PMid:17592743

3. Stuart CA, Gilkison CR, Smith MM, Bosma AM, Keenan BS, Nagamani M. Acanthosis nigricans as a risk factor for non-insulin dependent diabetes mellitus. Clin Pediatr (Phila). 1998; 37(2):73-9. https://doi.org/10.1177/000992289803700203 PMid:9492114

4. Hodak E, Gottlieb AB, Anzilotti M, Krueger JG. The insulin-like growth factor 1 receptor is expressed by epithelial cells with proliferative potential in human epidermis and skin appendages: correlation of increased expression with epidermal hyperplasia. J Invest Dermatol. 1996; 106(3):564-70. https://doi.org/10.1111/1523-1747.ep12344044 PMid:8648195

5. Lee JM, Okumura MJ, Davis MM, Herman WH, Gurney JG. Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study. Diabetes Care. 2006; 29(11):2427-32. https://doi.org/10.2337/dc06-0709 PMid:17065679

6. Muguet Guenot L, Aubert H, Isidor B, Toutain A, Mazereeuw-Hautier J, Collet C, Bourrat E, Denis Musquer M, Barbarot S; Groupe de Recherche de la Société Française de Dermatologie Pédiatrique. Acanthosis nigricans, hypochondroplasia, and FGFR3 mutations: Findings with five new patients, and a review of the literature. Pediatr Dermatol. 2019; 36(2):242-246. https://doi.org/10.1111/pde.13748 PMid:30762251

7. Mueller N, Sassa T, Morales-Gonzalez S, Schneider J, Salchow DJ, Seelow D, Knierim E, Stenzel W, Kihara A, Schuelke M. De novo mutation in ELOVL1 causes ichthyosis, acanthosis nigricans, hypomyelination, spastic paraplegia, high-frequency deafness and optic atrophy. J Med Genet. 2019; 56(3):164-175. https://doi.org/10.1136/jmedgenet-2018-105711 PMid:30487246

8. Ellis DL, Kafka SP, Chow JC, Nanney LB, Inman WH, McCadden ME, King LE Jr. Melanoma, growth factors, acanthosis nigricans, the sign of Leser-Trélat, and multiple acrochordons. A possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes. N Engl J Med. 1987; 317(25):1582-7. https://doi.org/10.1056/NEJM198712173172506 PMid:2825016

9. Unal E, Guarneri C, Chokoeva AA, Wollina U, Tchernev G. Terra

firma-forme dermatosis. Wien Med Wochenschr. 2017; 167(3-4):66-69. https://doi.org/10.1007/s10354-016-0519-1 PMid:27770322

10. Lim JH, Tey HL, Chong WS. Confluent and reticulated papillomatosis: diagnostic and treatment challenges. Clin Cosmet Investig Dermatol. 2016; 9:217-23. https://doi.org/10.2147/CCID.S92051 PMid:27601929 PMCid:PMC5003519

11. Lautenschlager S, Itin PH. Reticulate, patchy and mottled pigmentation of the neck. Acquired forms. Dermatology. 1998; 197(3):291-6. https://doi.org/10.1159/000018016 PMid:9812039

12. Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin North Am. 2014; 43(1):1-23. https://doi.org/10.1016/j.ecl.2013.09.009 PMid:24582089

13. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006; 295(13):1549-55. https://doi.org/10.1001/jama.295.13.1549 PMid:16595758

14. Ozlu E, Uzuncakmak TK, Takır M, Akdeniz N, Karadag AS. Comparison of cutaneous manifestations in diabetic and nondiabetic obese patients: A prospective, controlled study. North Clin Istanb. 2018; 5(2):114-119. https://doi.org/10.14744/nci.2017.68553 PMid:30374476 PMCid:PMC6191549

15. Palhares HMDC, Zaidan PC, Dib FCM, Silva APD, Resende DCS, Borges MF. Association between acanthosis nigricans and other cardiometabolic risk factors in children and adolescents with overweight and obesity. Rev Paul Pediatr. 2018;36(3):301-308. https://doi.org/10.1590/1984-0462/;2018;36;3;00017 PMid:30365811 PMCid:PMC6202888

16. Karadağ AS, You Y, Danarti R, Al-Khuzaei S, Chen W. Acanthosis nigricans and the metabolic syndrome. Clin Dermatol. 2018; 36(1):48-53. https://doi.org/10.1016/j.clindermatol.2017.09.008 PMid:29241752

17. Higgins SP, Freemark M, Prose NS. Acanthosis nigricans: a practical approach to evaluation and management. Dermatol Online J. 2008; 14(9):2.

18. Kazemi M, Pierson RA, Lujan ME, Chilibeck PD, McBreairty LE, Gordon JJ, Serrao SB, Zello GA, Chizen DR. Comprehensive Evaluation of Type 2 Diabetes and Cardiovascular Disease Risk Profiles in Reproductive-Age Women with Polycystic Ovary Syndrome: A Large Canadian Cohort. J Obstet Gynaecol Can. 2019; S1701-2163(18)30991-5. https://doi.org/10.1016/j.jogc.2018.11.026 PMid:30712903

19. Ramos-E-Silva M, Carvalho JC, Carneiro SC. Cutaneous paraneoplasia. Clin Dermatol. 2011; 29(5):541-7. https://doi.org/10.1016/j.clindermatol.2010.09.022 PMid:21855730

20. Krawczyk M, Mykała-Cieśla J, Kołodziej-Jaskuła A. Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature. Pol Arch Med Wewn. 2009; 119:180-183. https://doi.org/10.20452/pamw.642 PMid:19514649

21. Levine D, Miller S, Al-Dawsari N, Barak O, Gottlieb AB. Paraneoplastic dermatoses associated with gynecologic and breast malignancies. Obstet Gynecol Surv. 2010; 65(7):455-61. https://doi.org/10.1097/OGX.0b013e3181efb12a PMid:20723267

22. Scully C, Barrett WA, Gilkes J, Rees M, Sarner M, Southcott RJ. Oral acanthosis nigricans, the sign of Leser-Trélat and cholangiocarcinoma. Br J Dermatol. 2001; 145(3):506-7. https://doi.org/10.1046/j.1365-2133.2001.04393.x PMid:11531848

23. Ferraz de Campos FP, Narvaez MR, Reis PV, Gomes AC, Paraskevopoulos DK, Santana F, Fugita OE. Acanthosis Nigricans associated with clear-cell renal cell carcinoma. Autops Case Rep. 2016; 6(1):33-40. https://doi.org/10.4322/acr.2016.021 PMid:27284539 PMCid:PMC4880432

24. Deen J, Moloney T, Burdon-Jones D. Severe, Malignant Acanthosis Nigricans Associated with Adenocarcinoma of the Endometrium in a Young Obese Female. Case Rep Dermatol. 2017; 9(1):30-37. https://doi.org/10.1159/000456652 PMid:28413386 PMCid:PMC5346941

25. West L, Carlson M, Wallis L, Goff HW. The Sign of Leser-Trelát and Malignant Acanthosis Nigricans Associated With Fallopian Tube Carcinoma. Obstet Gynecol. 2018; 132(5):1116-1119. https://doi.org/10.1097/AOG.0000000000002920 PMid:30303917

26. Ziadi T, Alahyane A, El Fahssi M, Makhmari R, Elhjouji A, Baba H, Ould Jiddou C, Nafae I, Mejdane A, Bounaim A, Ait Ali A, Zentar A, Hommadi A, Sair K. [Adenocarcinoma of gallbladder revealed by acanthosis nigricans]. Gastroenterol Clin Biol. 2009; 33(10-11):986-8. https://doi.org/10.1016/j.gcb.2009.06.010 PMid:19765931

27. Yu Q, Li XL, Ji G, Wang Y, Gong Y, Xu H, Shi YL. Malignant acanthosis nigricans: an early diagnostic clue for gastric adenocarcinoma. World J Surg Oncol. 2017; 15(1):208. https://doi.org/10.1186/s12957-017-1274-5 PMid:29178944 PMCid:PMC5702104

28. Mignogna MD, Fortuna G, Falleti J, Leuci S. Gastric diffuse large B-cell lymphoma (DLBCL) exhibiting oral acanthosis nigricans and tripe palms. Dig Liver Dis. 2009; 41(10):766-8. https://doi.org/10.1016/j.dld.2009.02.049 PMid:19349220

29. Park KW, Lim DH, Lee SI. Malignant acanthosis nigricans in a patient with a gastrointestinal stromal tumor. Korean J Intern Med. 2013; 28(5):632-3. https://doi.org/10.3904/kjim.2013.28.5.632 PMid:24009466 PMCid:PMC3759776

30. Antonio JR, Trídico LA, Antonio CR. Malignant Acanthosis nigricans associated with early diagnosis of liver cancer. An Bras Dermatol. 2018; 93(4):616-617. https://doi.org/10.1590/abd1806-4841.20187560 PMid:30066784 PMCid:PMC6063124

31. Gunduz K, Coban M, Oztürk F, Ermertcan AT. Malignant acanthosis nigricans associated with ileocecal adenocarcinoma. Cutan Ocul Toxicol. 2013; 32(2):173-5. https://doi.org/10.3109/15569527.2012.713417 PMid:22916843

32. Patra S, Chakraborty PP, Barman H, Santra G. Acanthosis nigricans in insulinoma: before and after successful surgical enucleation. BMJ Case Rep. 2016; 2016:bcr2016218003. https://doi.org/10.1136/bcr-2016-218003 PMid:27836838 PMCid:PMC5128931

33. Owen CE. Cutaneous manifestations of lung cancer. Semin Oncol. 2016; 43(3):366-9. https://doi.org/10.1053/j.seminoncol.2016.02.025 PMid:27178690

34. Dainichi T, Moroi Y, Duan H, Urabe K, Koga T, Miyazono M, Sasaki T, Hashimoto T, Furue M. Paraneoplastic acanthosis nigricans and silent meningioma producing transforming growth factor-alpha. Eur J Dermatol. 2008; 18(6):721-2.

35. Cheng E, Roy DB, Magro CM. A case of acanthosis nigricans coexisting with mycosis fungoides. Dermatol Online J. 2015; 21(7).

36. Fahmy J, Halabi-Tawil M, Ram-Wolff C, Bagot M, Petit A. Paraneoplastic acanthosis nigricans: the first reported case associated with Sézary syndrome. Br J Dermatol. 2016; 174(1):233-4. https://doi.org/10.1111/bjd.14065 PMid:26264676

37. Singh SK, Rai T. A rare case of malignant acanthosis nigricans in a lady with ovarian cancer. Indian Dermatol Online J. 2013; 4(2):125-7. https://doi.org/10.4103/2229-5178.110640 PMid:23741672 PMCid:PMC3673379

38. McGinness J, Greer K. Malignant acanthosis nigricans and tripe palms associated with pancreatic adenocarcinoma. Cutis. 2006; 78(1):37-40.

39. Tammaro A, Giulianelli V, Parisella F, Persechino S. Bilaterally mammary acanthosis nigricans as paraneoplastic manifestation of prostate adenocarcinoma. G Ital Dermatol Venereol. 2016; 151(5):578-9.

40. Marschner ML, Reinhardt JF. Malignant acanthosis nigricans in rectal adenocarcinoma. Del Med J. 2011; 83(8):247-9.

41. Brantsch KD, Moehrle M. Acanthosis nigricans in a patient with sarcoma of unknown origin. J Am Acad Dermatol. 2010; 62(3):527-8. https://doi.org/10.1016/j.jaad.2009.02.010 PMid:20159329